Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.54 |
| ▸ | MAPT | P10636 | 6/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 5/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | DDX3X | O00571 | 2/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | PANK3 | Q9H999 | 1/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2832601 | 0.88 | RAB9A (0.50) | L3MBTL1MAPTRAB9ANPSR1KDM4E | |
| SCHEMBL2826663 | 0.88 | PTPN11 (0.54) | L3MBTL1MAPTCYP1A2RAB9AHRH3 | |
| SCHEMBL2829625 | 0.83 | HRH3 (0.54) | L3MBTL1MAPTRAB9AHRH3KDM4E | |
| SCHEMBL2831832 | 0.83 | DRD2 (0.54) | L3MBTL1MAPTRAB9AHRH3IMPDH2 | |
| Cyclohexane SCHEMBL2828762 | 0.80 | L3MBTL1 (0.52) | L3MBTL1MAPTCYP1A2RAB9AHRH3 | |
| SCHEMBL2829567 | 0.80 | NAMPT (0.47) | L3MBTL1MAPTRAB9AHRH3KDM4E | |
| SCHEMBL2829341 | 0.79 | SMN1; SMN2 (0.57) | MAPTRAB9AHRH3KDM4ENPC1 | |
| SCHEMBL2826808 | 0.77 | NPC1 (0.53) | L3MBTL1MAPTCYP1A2RAB9AHRH3 | |
| SCHEMBL2829620 | 0.76 | HRH3 (0.53) | L3MBTL1MAPTCYP1A2RAB9AHRH3 | |
| SCHEMBL2826056 | 0.76 | CNR1 (0.51) | L3MBTL1NPSR1HRH3HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1824829-B1 | 3-SUBSTITUTED PYRIDINE DERIVATIVES AS H3 ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2010-05-05 | — | — | EP | claimed |
| CN-101068786-A | 3-substituted pyridine derivatives as h3 antagonists | HOFFMANN LA ROCHE (CH) | 2007-11-07 | — | — | CN | claimed |
| EP-1824829-A1 | 3-SUBSTITUTED PYRIDINE DERIVATIVES AS H3 ANTAGONISTS | F. Hoffmann-Roche AG (CH) | 2007-08-29 | — | — | EP | claimed |
| US-20060122187-A1 | Pyridine derivatives as H3 antagonists | F. HOFFMANN-LA ROCHE AG (CH) | 2006-06-08 | — | — | US | claimed |
| WO-2006058649-A1 | 3-SUBSTITUTED PYRIDINE DERIVATIVES AS H3 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-06-08 | — | — | WO | claimed |
| EP-1824829-B1 | 3-SUBSTITUTED PYRIDINE DERIVATIVES AS H3 ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2010-05-05 | — | — | EP | disclosed |
| US-7528135-B2 | Pyridine derivatives as H3 antagonists | HOFFMANN-LA ROCHE INC. (US) | 2009-05-05 | — | — | US | disclosed |
| CN-101068786-A | 3-substituted pyridine derivatives as h3 antagonists | HOFFMANN LA ROCHE (CH) | 2007-11-07 | — | — | CN | disclosed |
| EP-1824829-A1 | 3-SUBSTITUTED PYRIDINE DERIVATIVES AS H3 ANTAGONISTS | F. Hoffmann-Roche AG (CH) | 2007-08-29 | — | — | EP | disclosed |
| US-20060122187-A1 | Pyridine derivatives as H3 antagonists | F. HOFFMANN-LA ROCHE AG (CH) | 2006-06-08 | — | — | US | disclosed |
| WO-2006058649-A1 | 3-SUBSTITUTED PYRIDINE DERIVATIVES AS H3 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122187-A1 | Pyridine derivatives as H3 antagonists | HRH3, HRH4, HRH2 | L3MBTL1 2623/4885MAPT 2111/4885CYP1A2 455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.